India’s pharmaceutical market is projected to rise further at around 8–9% annually, reaching ₹3.0–3.2 trillion by FY2029. Corona Remedies Limited, a company working in this sector, is gearing up for the IPO.
The IPO is managed by IIFL Capital Services, JM Financial, and Kotak Mahindra Capital. Moreover, Bigshare Services is registering the issue. Check the Corona Remedies IPO allotment status now.
To know more about the IPO, check out the Corona Remedies IPO DRHP.
Note: 50% shares will be unlocked 30 days after allotment, while the rest will be free from lock-in restrictions after 90 days.
Here is the full Corona Remedies IPO review.
The company filed its draft papers with SEBI and the exchange on May 5, 2025, and received approval on August 29, 2025. However, details about the IPO’s opening and closing dates have not been announced yet.
The purpose of this Offer is to carry out an Offer for Sale by the selling shareholders. The company itself won’t get any funds from this Offer. All proceeds will go directly to the selling shareholders.
Let's see the risks and strengths you should know about Corona Remedies:
Strong Market Growth: The company is one of the fastest-growing players among India’s top 30 pharma firms, showing impressive growth in domestic sales from 2021 to 2024.
Wide Product Portfolio: It has built a well-balanced mix of medicines, including its key “engine” brands.
All-India Presence: With a strong sales and marketing network across the country, the company focuses on the mid-income group.
Focus on Innovation: Its advanced manufacturing units follow top-quality and Good Manufacturing Practice standards.
Risks
Reliance on a Few Star Brands: A big part of the company’s sales comes from a few strong brands. If these brands lose popularity or face tough competition, it could affect the company’s overall revenue.
Mostly Dependent on the Indian Market: Since almost all of the company’s earnings come from India, any drop in local demand in expanding overseas could slow down its growth.
Sales Focused in Limited States: Many of the company’s sales come from states like Gujarat, Maharashtra, Goa, Madhya Pradesh, and Chhattisgarh.
Heavy Focus on a Few Therapy Segments: The company earns most of its money from women’s health, pain management, and cardio-diabetic products. If demand in these categories falls, profits could take a hit.
As of November 4, 2025, the Corona Remedies IPO GMP hasn’t been updated yet. You can still check the IPO's live GMP and the subscription status numbers. Also, it’s a good idea to run through the Corona Remedies DRHP before you hit Apply Now.
1. How is the Corona Remedies IPO review?
Corona Remedies Limited is a pharmaceutical company. However, you can check the IPO date, size, and Corona Remedies turnover in its DRHP. For the latest details, you can also look for the GMP updates.
2. What is the Corona Remedies Ltd IPO date?
The IPO open and the close date are unavailable as of November 4, 2025. Live subscription details can be monitored through Finnpick.
3. What is the Corona Remedies share price?
The Corona Remedies share price target 2025 is unavailable as of November 4, 2025. Also, don't forget to check the Corona Remedies IPO news.
4. Should I use a demat account to bid for the Corona Remedies Limited IPO?
Yes, a demat account is required to bid for the Corona Remedies Limited IPO. Click here to get the ultimate list of the top demat account providers.
